NPS Pharmaceuticals weakness attributed to comments on Natpara NPS Pharmaceuticals management said at a conference hosted by Deutshce Bank that it does not know if an FDA panel will be need for Natpara, according to Bloomberg. The company said it doesn't expect a priority review for Natpara, the news service added. Shares of NPS have fallen to session lows, down 7.7% to $24.04.
Deutsche Bank to host a conference BioFest is being held in Boston on December 2-3 with webcasted company presentations to begin on December 3 at 7:50 am; not all company presentations may be webcasted. Webcast Link